Safety & Interactions

Known human safety profile

Apigenin has a long dietary history with no evidence of intrinsic toxicity at food-level intake.

In animal studies, including pharmacological dosing, no consistent signal of major body-weight loss or organ toxicity has been reported. Even at high oral doses in rodent work, overt toxicity has generally not been observed.

At higher supplemental doses, mild sedation and muscle relaxation have been reported. Apigenin is a low-affinity benzodiazepine-receptor ligand, which helps explain the anxiolytic effect associated with chamomile. That is not usually dangerous, but it matters for people already taking sedatives.

Long-term safety at pharmacological doses has not been formally established in humans.

Drug interaction concerns

This is the most clinically relevant section for anyone in active treatment.

CYP2C9 inhibition

Apigenin is a potent CYP2C9 inhibitor in vitro, with potency comparable to some pharmaceutical CYP inhibitors.

CYP2C9 processes a wide range of drugs, including several NSAIDs, warfarin, some antiepileptics, and sulfonylurea antidiabetics. Inhibiting this pathway at pharmacological apigenin doses could raise drug levels and increase toxicity risk.

The evidence is still largely in vitro, but strong enough to take seriously.

CYP3A4 inhibition

Apigenin also inhibits CYP3A4, which metabolises a large proportion of pharmaceuticals, including many chemotherapies, immunosuppressants, and targeted agents.

The exact strength of inhibition at achievable human tissue concentrations remains uncertain. The interaction potential is still real.

Imatinib and related kinase inhibitors

A pharmacokinetic animal study found a bidirectional, time-dependent interaction.

Short-term apigenin co-administration inhibited imatinib metabolism and raised exposure. Long-term co-administration appeared to accelerate metabolism and lower exposure.

This matters for anyone using imatinib or related kinase inhibitors.

ABC transporter inhibition

Apigenin inhibits drug-efflux transporters including P-glycoprotein and BCRP in intestinal epithelial models.

That may raise intracellular concentrations of co-administered drugs and adds a second interaction layer beyond CYP enzymes.

Anticoagulants

Because CYP2C9 is central to warfarin metabolism, there is a plausible interaction risk with anticoagulants.

This follows directly from the enzyme data, even though dedicated clinical confirmation is still lacking.

Endocrine considerations

Apigenin has weak oestrogenic and anti-oestrogenic activity depending on context.

It is far less potent than isoflavones, but this still warrants awareness in oestrogen receptor-positive settings.

Liver and kidney

No hepatotoxicity or nephrotoxicity signal stands out in the available literature. Apigenin has even shown hepatoprotective effects in liver-injury models.

That does not rule out clinically relevant interactions with liver-processed drugs at supplemental doses above normal dietary exposure.

Key principle

Plant-derived does not mean interaction-free.

The CYP2C9, CYP3A4, and transporter concerns are real and relevant for anyone using active treatment, especially drugs with narrow therapeutic windows. Most interaction signals are still theoretical or preclinical rather than confirmed in human case series, but they warrant careful attention.

How to interpret interaction evidence

Cell and laboratory findings can identify a possible interaction. They do not confirm the same effect occurs in people.

Read interaction claims alongside human pharmacokinetic and clinical evidence. See Drug Interaction Evidence and CYP Enzymes for the evidence hierarchy and practical questions to ask.

References

• Alzheimer's Drug Discovery Foundation. Apigenin Cognitive Vitality Researcher Summary

• Hou X, et al. Food polyphenol apigenin inhibits the cytochrome P450 monooxygenase branch of the arachidonic acid cascade

• Lan T, et al. The Effect of Apigenin on Pharmacokinetics of Imatinib and Its Metabolite

• Chmielewska M, et al. Does Oral Apigenin Have Real Potential for a Therapeutic Effect in Cancer?